Guidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment

Evidence supporting the routine, nonselective use of NGS in patients with sarcoma is currently limited. Given the complexity, the decision to perform an NGS panel, as well as the interpretation and use of its results for diagnostic or therapeutic purposes, should take place only in sarcoma-expert institutions, including a multidisciplinary review. The results of multigene panels performed in nonexpert sarcoma centers cannot replace the pathology review or the recommendation of NGS-guided therapies without prior evaluation by sarcoma experts.

Corresponding Authors: César Serrano, MD, PhD, Sarcoma Translational Research Group, Vall d’Hebron Institute of Oncology, C/ Natzaret, 115-117, 08035 Barcelona, Spain (cserrano@vhio.net); Judith V. M. G. Bovée, MD, PhD, Department of Pathology, Leiden University Medical Center, Leiden, Zuid-Holland, the Netherlands (j.v.m.g.bovee@lumc.nl).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.